Comprehensive Psychiatry
Volume 48, Issue 5 , Pages 436-440 , September 2007

Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study

  • Diederik E. Tenback

      Affiliations

    • Psychiatric Center Altrecht, P.O. Box 18, 3734 ZG Den Dolder, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 348 427111; fax: +31 348 427160.
    • ,
  • Peter N. van Harten

      Affiliations

    • Psychiatric Center Symfora Group, P.O. Box 3051, 3800 DB Amersfoort, The Netherlands
    • University Medical Center Groningen, Groningen, The Netherlands
    • ,
  • Cees J. Slooff

      Affiliations

    • Department of Psychotic Disorders, Mental Health Centre Drenthe, Assen, The Netherlands
    • ,
  • Jim van Os

      Affiliations

    • Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University, Maastricht, The Netherlands
    • Division of Psychological Medicine, Institute of Psychiatry, London, UK
    • ,
  • SOHO Study Group

References 

  1. Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology. 1994;11(2):107–118
  2. Murray RM, Van Os J. Predictors of outcome in schizophrenia. J Clin Psychopharmacol. 1998;18(2 Suppl 1):2S–4S
  3. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol. 1988;8(4 Suppl):21S–26S
  4. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am J Psychiatry. 1979;136(1):79–82
  5. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry. 1996;53(4):313–319
  6. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. 2004;38(6):445–449
  7. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry. 2003;64(9):1075–1080
  8. Waddington JL, Youssef HA, Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med. 1990;20(4):835–842
  9. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand. 2003;107(3):222–232
  10. Guy W, American Psychiatric Association . Task force for the handbook of psychiatric measures. (2000). In: Handbook of psychiatric measures. Washington (DC): American Psychiatric Association; 1976;p. 100–102
  11. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;(416):16–23
  12. Stata Corp . STATA statistical software: release 8.0. Texas: College Station; 2002;
  13. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry. 2006;163(8):1438–1440
  14. Tenback DE, van Harten PN, Slooff CJ, van Os J. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology. 2006;31(8):1832–1837
  15. Hill AB. The environment and disease: association or causation?. Proc R Soc Med. 1965;58:295–300
  16. Chouinard G, Annable L, Ross-Chouinard A. Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull. 1986;22(3):891–896
  17. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978;135(11):1409–1410
  18. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514–520
  19. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33–43
  20. Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse. 2000;26(3):343–353
  21. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull. 1997;33(1):177–181
  22. Duke PJ, Pantelis C, Barnes TR. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry. 1994;164(5):630–636
  23. Zaretsky A, Rector NA, Seeman MV, Fornazzari X. Current cannabis use and tardive dyskinesia. Schizophr Res. 1993;11(1):3–8
  24. Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand Suppl. 1996;389:12–17
  25. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998;155(4):565–567
  26. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–667
  27. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr Res. 2005;77(2-3):119–128
  28. Hofler M. The effect of misclassification on the estimation of association: a review. Int J Methods Psychiatr Res. 2005;14(2):92–101
  29. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005;66(9):1130–1133
  30. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425
  31. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553–564
  32. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209–1222

PII: S0010-440X(07)00059-4

doi: 10.1016/j.comppsych.2007.05.003

Comprehensive Psychiatry
Volume 48, Issue 5 , Pages 436-440 , September 2007

Article Tools